Final results of phase III SYMMETRY study: Randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma

Journal of Clinical Oncology

Volumn 31, Issue 9, 2013, Pages 1211-1218

  O'Day, Steven J ^a   Eggermont, Alexander M M ^b   Chiarion Sileni, Vanna ^e   Kefford, Richard ^g   Grob, Jean Jacques ^c   Mortier, Laurent ^d   Robert, Caroline ^b   Schachter, Jacob ^h   Testori, Alessandro ^f   Mackiewicz, Jacek ⁱ   Friedlander, Philip ^j   Garbe, Claus ^k   Ugurel, Selma ^m   Collichio, Frances ⁿ   Guo, Wei ^o   Lufkin, Joelle ^o   Bahcall, Safi ^o   Vukovic, Vojo ^o   Hauschild, Axel ^l  

^a Beverly Hills Cancer Center   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c TIMONE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF SYDNEY   (Australia)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^j MOUNT SINAI MEDICAL CENTER   (United States)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o Synta Pharmaceuticals Corp   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ELESCLOMOL; LACTATE DEHYDROGENASE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HUMAN; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; HYDRAZINES; L-LACTATE DEHYDROGENASE; MELANOMA; PACLITAXEL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84875980910     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.5585     Document Type: Article

References (33)

1. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2008. Bethesda, MD, National Cancer Institute, 2011. http://seer.cancer. gov/csr/1975-2008/
2. Agarwala SS: Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587-595, 2009
3. Patel PM, Suciu S, Mortier L, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomized phase III study (EORTC 18032). Eur J Cancer 47:1476-1483, 2011
4. Eggermont AM, Kirkwood JM: Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur J Cancer 40:1825-1836, 2004 (Pubitemid 39036756)
5. Eggermont AM: Immunotherapy: Vaccine trials in melanoma - Time for reflection. Nat Rev Clin Oncol 6:256-258, 2009
6. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
7. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
8. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97-110, 2004 (Pubitemid 38736063)
9. Trachootham D, Zhou Y, Zhang H, et al: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241-252, 2006 (Pubitemid 44311067)
10. Fruehauf JP, Trapp V: Reactive oxygen species: An Achilles' heel of melanoma? Expert Rev Anticancer Ther 8:1751-1757, 2008
11. Kirshner JR, He S, Balasubramanyam V, et al: Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7:2319-2327, 2008
12. Nagai M, Vo NH, Shin Ogawa L, et al: The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med 52:2142-2150, 2012
13. Blackman RK, Cheung-Ong K, Gebbia M, et al: Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS ONE 7:e29798, 2012
14. Koya K, Sun L, Chen S, et al: STA-4783, a novel HSP70 inducer, enhances the anti-cancer activity of paclitaxel without increasing toxicity in pre-clinical studies. Proc Amer Assoc Cancer Res 45, 2004 (abstr 1504)
15. Foley KP, Bertin J, Allen I, et al: Elesclomol (formerly STA-4783) induces oxidative stress selectively in cancer cells and inhibits tumor growth in combination with paclitaxel and carboplatin in mouse tumor models. Presented at the Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12-16, 2008
16. O'Day S, Gonzalez R, Lawson D, et al: Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 27:5452-5458, 2009
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011
19. Ribas A, Hauschild A, Kefford R, et al: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26:485s, 2008 (suppl; abstr LBA9011)
20. Byhardt RW, Hartz A, Libnoch JA, et al: Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 12:771-777, 1986 (Pubitemid 16033475)
21. Magrath I, Lee YJ, Anderson T, et al: Prognostic factors in Burkitt's lymphoma: Importance of total tumor burden. Cancer 45:1507-1515, 1980 (Pubitemid 10134890)
22. Fleisher M, Wasserstrom WR, Schold SC, et al: Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer 47:2654-2659, 1981 (Pubitemid 11113731)
23. Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer 51:840-843, 1983 (Pubitemid 13143161)
24. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237, 2009
25. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540, 2012
26. Kim KB, Sosman JA, Fruehauf JP, et al: BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30:34-41, 2012
27. Armstrong AJ, George DJ, Halabi S: Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with met-astatic renal cell carcinoma (RCC). J Clin Oncol 28:374s, 2010 (suppl; abstr 4631)
28. Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
29. Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010, 2011
30. Dachs GU, Stratford IJ: The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer Suppl 27:S126-S132, 1996 (Pubitemid 26237945)
31. Abraham RT: mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 279:299-319, 2004
32. Semenza GL: HIF-1: Using two hands to flip the angiogenic switch. Cancer Metastasis Rev 19: 59-65, 2000 (Pubitemid 32004693)
33. Nagai M, Blackman RK, Rao PE, et al: Anticancer activity of elesclomol correlates with low LDH levels and active mitochondrial respiration. Presented at the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010 (abstr 4545)